Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group

Keyphrases

• Neoantigen 100%
• Precision Medicine 100%
• Clinical Benefit 100%
• Neoantigen Prediction 100%
• European Society for Medical Oncology 100%
• Computational Perspective 100%
• Benefits Recommendation 100%
• Tumor-specific 60%
• Cancer Vaccine 40%
• Cancer Types 40%
• Adoptive Cell Therapy 40%
• Somatic mutation 20%
• Gene Expression 20%
• Tumor Cells 20%
• T Cell Response 20%
• Antitumor T Cells 20%
• Clinical Efficacy 20%
• Cancer Cells 20%
• Aberrations 20%
• Frameshift 20%
• Clinical Trial Development 20%
• Clonality 20%
• Gene Fusion 20%
• Rapid Identification 20%
• High-throughput Sequencing 20%
• Cancer Immunotherapy 20%
• Next-generation Sequencing Technology 20%
• Nonsynonymous 20%
• Immunogenic 20%
• Tumor mutation Burden 20%
• Host Immunity 20%
• Immune Therapy 20%
• All Cancer 20%
• Ongoing Clinical Trials 20%
• Antigen-specific T Cell Response 20%
• Mutant Allele Frequency 20%
• Splice Variant 20%
• Tumor-specific T Cells 20%
• PMHC 20%
• Computational pipeline 20%
• Somatic mutations in Cancer 20%
• Tumor Neoantigens 20%
• Immunogenic Tumor 20%
• Personalized Neoantigen 20%
• Tumor-specific Peptides 20%
• Binding Affinity Prediction 20%
• Recent Approaches 20%
• Endogenous Retroelements 20%
• Mutant Peptide 20%
• Neoantigen Identification 20%

Medicine and Dentistry

• Personalized Medicine 100%
• Specific Tumor 100%
• Medical Oncology 100%
• Immunotherapy 60%
• Somatic Mutation 40%
• Clinical Trial 40%
• T-Cell Response 40%
• Cancer Types 40%
• T Cell 40%
• Cell Therapy 40%
• Tumor Vaccine 40%
• Cancer Cell 20%
• Tumor Cell 20%
• Allele 20%
• Gene Expression 20%
• Tumor 20%
• Next Generation Sequencing 20%
• Systematic Review 20%
• Gene Fusion 20%
• Clonal Variation 20%
• Cancer Immunotherapy 20%
• Binding Affinity 20%
• Tumor Mutation Burden 20%
• Retroposon 20%
• Major Histocompatibility Complex Peptide 20%

Biochemistry, Genetics and Molecular Biology

• T Cell 100%
• Somatic Mutation 50%
• Clinical Trial 50%
• Gene Expression 25%
• Cancer Cell 25%
• Allele 25%
• Next Generation Sequencing 25%
• Binding Affinity 25%
• Clonality 25%
• Clonal Variation 25%
• Gene Fusion 25%
• High Throughput Sequencing 25%
• Retrotransposon 25%
• Cancer Immunotherapy 25%
• Major Histocompatibility Complex Peptide 25%